Bio-Thera Moves Ahead With Secukinumab And Mepolizumab
Chinese Player’s Biosimilar Rivals To Cosentyx And Nucala Take Steps Forward
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).
